Skip to main content
Figure 6 | Molecular Neurodegeneration

Figure 6

From: rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration

Figure 6

rAAV2/7 vector-mediated α-synuclein overexpression in mouse SN leads to motor behaviour impairments. (A) Performance in the cylinder test of rAAV2/7-eGFP and rAAV2/7-α-synuclein WT mice at 1 week, 4 weeks, 8 weeks and 12 weeks after injection. No asymmetry in forepaw use was detected up to 8 weeks. At 12 weeks after injection, a significantly reduced use of the contralateral forepaw was observed for the mid dose of α-synuclein vector. (B) The rotarod test performed at 14 weeks after injection showed a significant reduction in average time on the rotating rod for both rAAV2/7-α-synuclein doses. (C) A significant decline in the walking distance was observed for the two α-synuclein doses tested in the open field at 15 weeks after injection. For all tests: 8,0E + 11 GC/ml eGFP/WT and 4,0E + 11 GC/ml WT: n = 10.

Back to article page